Different interferons: Pharmacology, pharmacokinetics, proposed mechanisms, safety and side effects;Les différents interférons: Pharmacologie, mécanismes d'action, tolérance et effets secondaires

Revue de Medecine Interne

Volumn 23, Issue SUPPL. 4, 2002, Pages

  Arnaud, Philippe ^a  

^a HÔPITAL CHARLES NICOLLE   (France)

Author keywords

Interferons; Pharmacodynamics; Pharmacokinetics; Safety; Side effects

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; BETA INTERFERON; BETA1A INTERFERON; CONSENSUS INTERFERON; GAMMA INTERFERON; INTERFERON; INTERFERON BETA SERINE; MACROGOL; MAJOR HISTOCOMPATIBILITY ANTIGEN; NEUTRALIZING ANTIBODY; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGINTERFERON BETA2B; PROTEIN KINASE; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; SYNTHETASE; UNCLASSIFIED DRUG;

ANOREXIA; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ANTIVIRAL ACTIVITY; ARTHRALGIA; ASTHENIA; AUTOIMMUNE DISEASE; BLOOD TOXICITY; CARDIOTOXICITY; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EYE TOXICITY; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; INFECTION; LETHARGY; LIVER TOXICITY; LUNG TOXICITY; MALAISE; MENSTRUATION DISORDER; MYALGIA; NATURAL KILLER CELL; NAUSEA; NEUROMUSCULAR DISEASE; NEUROTOXICITY; PROTEIN SYNTHESIS INHIBITION; REVIEW; RNA DEGRADATION; THYROID DISEASE; VOMITING;

EID: 0036854280     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(02)00659-8     Document Type: Article

References (22)

1. Mitsikostas DD. The case for interferon beta 1a (Rebif®) treatment in relapsing multiple sclerosis. J Clin Res 2001;4:1-17.
2. Harris JM, Martin NE, Modi M. Pegylation. A novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001;40:539-51.
3. Perry CM, Jarvis B. Peginterferon alpha 2a (40kD). A review of its use in the management of chronic hepatitis C. Drugs 2001;61:2263-88.
4. Kozlowski A, Charles SA, Harris JM. Development of pegylated interferons for the treatment of chronic hepatitis C. Biodrugs 2001;15:419-29.
5. Pol S, Zylberberg H. Interférons: Des mécanismes d'action aux applications cliniques en hépatologie. Médecine Thérapeutique 1998;4:323-31.
6. De Maeyer-Guignard J. Interférons alpha et beta. In: Cavaillon JM, editor. Les Cytokines. Paris: Masson; 1996. p. 335-47.
7. Meurs EF. Mécanismes d'action antivirale de l'interféron. Virologie 1997;1:481-97.
8. Gongora G, Mechti N. L'interféron: Un mécanisme complexe de signalisation. Bull Cancer 1999;86:911-9.
9. Le Page C, Sancéau J, Wietzerbin J. Mécanismes d'action des interférons. Hématologie 1997;3:309-18.
10. Jonasch E, Haluska FG. Interferon in oncological practice: Review of interferon biology, clinical applications, and toxicities. The Oncologist 2001;6:34-55.
11. Chieux V, Hober D, Chehadeh W, Wattré P. Interferon alpha, protéines antivirales et applications médicales. Ann Biol Clin 1999;57:659-66.
12. Marcellin P. Structure, fonctions et applications thérapeutiques des interférons. Ann Med Interne 1993;144:539-47.
13. Regad T, Chelbi-Alix MK. PML, un nouvel intermédiaire de l'effet antiviral de l'interféron. Médecine Sciences 2002;1:25-7.
14. Papo T. Interferon alpha et auto-immunité. Médecine Thérapeutique 2000;6:65-74.
15. Glue P, Fang JWS, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, et al. Pegylated interferon alpha 2b: Pharmacokinetics, pharmacodynamics, safety and preliminary efficacy data. Hepatitis C Intervention Therapy group. Clin Pharmacol Ther 2000;68:556-67.
16. Wills RJ, Dennis S, Spiegel HE, Gibson DM, Nadler PI. Interferon kinetics and adverse reactions after intravenous, intramuscular and subcutaneous injection. Clin Pharmacol Ther 1984;35:722-7.
17. Perry CM, Jarvis B. Peginterferon-alpha-2a (40 KD): A review of its use in management of chronic hepatitis C. Drugs 2001;61:2263-88.
18. Xu ZX, Hoffman J, Patel I, Joubert P. Single-dose safety/tolerability and pharmacokinetic/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated-interferon (PEG-IFN) and interferon-2a (IFN-2a) to healthy subjects. Hepatology 1998;28 Suppl:702A.
19. Rajender Reddy KR, Modi MW, Pedder S. Use of peginterferon alfa-2a (40KD) (Pegasys®) for the treatment of hepatitis C. Adv Drug Deliv Rev 2002;54:571-86.
20. Fried MW, Shiffman ML, Reddy KR, Smithh C, Marinos G, Gonçales FL, et al. Peginterferon alfa-2a plus ribavirine for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
21. Vial T, Choquet-Kastylevsky G, Liautard C, Descotes J. Endocrine and neurological adverse effects of the therapeutics interferons. Toxicology 2000;142:161-72.
22. Papo T. Interféron et auto-immunité. Rev Méd Interne 2002;23:501-10.